(This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here.)
Greetings from the always-lovely San Diego. Adam Feuerstein, here, and as you can see from the sunrise photo above, I am still very much on East Coast time. (Nice view from my hotel room, however.) I have traveled a great distance to bring you news and analysis from the annual meeting of the American Society of Hematology. And I’m not alone! Joining me are fellow STAT reporters (and West Coast denizens, all) Jonathan Wosen, Angus Chen, and Meghana Keshavan. Let’s roll.
Sanofi advances a new treatment for a rare, platelet-destroying disease
An oral treatment developed by the French pharma giant Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder that causes the body to attack and destroy its own blood-clotting platelets.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
